Korean J Physiol Pharmacol.  2013 Dec;17(6):525-530. 10.4196/kjpp.2013.17.6.525.

Functional Characterization of ABCB4 Mutations Found in Low Phospholipid-Associated Cholelithiasis (LPAC)

• Kim TH
• Park HJ
• Choi JH

• KMID: 2285480
• DOI: http://doi.org/10.4196/kjpp.2013.17.6.525

Abstract

Multidrug resistance 3 (MDR3) is expressed on the canalicular membrane of the hepatocytes and plays an important role in protecting the liver from bile acids. Altered ABCB4 gene expression can lead to a rare hepatic disease, low phospholipid-associated cholelithiasis (LPAC). In this study, we characterized 3 ABCB4 mutations in LPAC patients using various in vitro assay systems. We first measured the ability of each mutant to transport paclitaxel and then the mechanisms by which these mutations might change MDR3 transport activity were determined using immunoblotting, cell surface protein biotinylation, and immunofluorescence. Through a membrane vesicular transport assay, we observed that the uptake of paclitaxel was significantly reduced in membrane vesicles expressing 2 ABCB4 mutations, F165I and S320F. Both mutants showed significantly decreased total and cell surface MDR3 expression. These data suggest two missense mutations of ABCB4 may alter function of MDR3 and ultimately can be determined as LPAC-causing mutations.

Keyword

ABCB4; Functional characterization; LPAC; MDR3; Mutation

MeSH Terms

Bile Acids and Salts
Biotinylation
Cholelithiasis*
Drug Resistance, Multiple
Fluorescent Antibody Technique
Gene Expression
Hepatocytes
Humans
Immunoblotting
Liver
Membranes
Mutation, Missense
Paclitaxel
Bile Acids and Salts
Paclitaxel

Figure

• 

  Fig. 1 Effect of ABCB4 mutants on the transport activity. Inside-out membrane vesicles were prepared after transfection of ABCB4 reference (REF) or mutant-bearing plasmids into HEK-293T cells and ATP-dependent transport of paclitaxel was measured using various concentrations of paclitaxel. Values for transport activity were obtained by subtracting the uptake in empty vector (EV, pcDNA3.1)-transfected cells from that in cells transfected with ABCB4 reference or mutant-bearing vectors, at each corresponding paclitaxel concentration. The X-axis represents paclitaxel concentration. The Y-axis represents the amount of inorganic phosphate which was produced by the ATPase activity of MDR3 during the transport of paclitaxel. The data shown represent mean±SD from 5 separate experiments, with each experiment performed in triplicate wells. *p<0.05 vs. reference.

• 

  Fig. 2 Effect of ABCB4 mutants on the MDR3 expression. (A) HEK-293T cells expressing reference or mutant ABCB4 genes were lysed and proteins were immunoblotted with antibodies against MDR3, neomycin phosphotransferase II (NPII), and β-actin. (B) HEK-293T cells expressing reference or mutant ABCB4 genes were surface biotinylated and proteins were immunoblotted with antibodies against MDR3, Na+/K+ ATPase α-1, and aldolase. Immunoblotting with the anti-aldolase antibody confirmed that the samples were not contaminated with the cytosolic fraction of MDR3 protein. The intensity of each band was normalized by neomycin phosphotransferase II and β-actin (A) or Na+/K+ ATPase α-1 (B). Data (mean±SD) are from 3 separate experiments. *p<0.05, **p<0.01 vs. reference.

• 

  Fig. 3 Subcellular localization of the ABCB4 mutants. Immunofluorescence was performed after transfection of ABCB4 reference or mutant-bearing plasmids into HEK-293T cells. MDR3 protein was detected using the P3II26 antibody and Alexa Fluor® 488 rabbit anti-mouse IgG (green). Plasma membrane was stained by CellMask Plasma Membrane stain solution (red).

Reference

1. Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 2007; 453:601–610. PMID: 16622704.

2. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 1994; 77:1071–1081. PMID: 7912658.

3. Rosmorduc O, Hermelin B, Boelle PY, Parc R, Taboury J, Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology. 2003; 125:452–459. PMID: 12891548.

4. Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, Hadchouel M. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology. 1996; 23:904–908. PMID: 8666348.

5. Eloranta ML, Heiskanen JT, Hiltunen MJ, Mannermaa AJ, Punnonen KR, Heinonen ST. Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur J Obstet Gynecol Reprod Biol. 2002; 104:109–112. PMID: 12206920.

6. Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T, Yokota H, Yatomi Y, Yoshida H, Goto J, Tsuji S, Suzuki H. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol. 2011; 79:241–250. PMID: 21056966.

7. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007; 17:47–60. PMID: 17264802.

8. Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis. 2007; 2:29. PMID: 17562004.

9. Poupon R, Rosmorduc O, Boëlle PY, Chrétien Y, Corpechot C, Chazouillères O, Housset C, Barbu V. Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients. Hepatology. 2013; 58:1105–1110. PMID: 23533021.

10. Delaunay JL, Durand-Schneider AM, Delautier D, Rada A, Gautherot J, Jacquemin E, Aït-Slimane T, Maurice M. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature. Hepatology. 2009; 49:1218–1227. PMID: 19185004.

11. Gautherot J, Durand-Schneider AM, Delautier D, Delaunay JL, Rada A, Gabillet J, Housset C, Maurice M, Aït-Slimane T. Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4. J Biol Chem. 2012; 287:5070–5078. PMID: 22184139.

12. Jang GH, Kim TH, Choe Y, Ham A, Choi JH. Functional characterization of genetic variations in the MDR3 promoter. Biochem Biophys Res Commun. 2013; 430:1312–1318. PMID: 23261441.

13. Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, Lee SH, Kim SW, Kim MK, Kim KH, In Lee B, Lee MG. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010; 20:249–256. PMID: 20216337.

14. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 2010; 627:92–98. PMID: 19903471.

15. Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, Bordo D, Coviello DA. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet. 2007; 15:1230–1238. PMID: 17726488.

16. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000; 275:23530–23539. PMID: 10918072.

17. Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, Johns SJ, Ferrin TE, Kwok P, Giacomini KM. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 2009; 9:127–136. PMID: 19172157.

18. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009; 4:1. PMID: 19133130.